Cadrenal to file for FDA Rare Pediatric Disease Designation for tecarfarin in Kawasaki

Cadrenal Therapeutics, Inc.

• Plans to submit RPDD request to FDA for tecarfarin to treat pediatric Kawasaki disease patients with coronary artery aneurysms.
• If RPDD granted and tecarfarin approved, eligible for Priority Review Voucher valued ~$200M (recent sales $180M-$205M).
• Dual-track strategy: Global Pharma (CAD-1005, Phase 3-ready for HIT) and Rare Disease (tecarfarin for Kawasaki).
• Company to present at BIO International Convention June 22-25, 2026, seeking partnerships.
• Kawasaki disease is leading cause of acquired heart disease in children; up to 25% untreated develop CAAs.